Recombinant

Caplacizumab (VWF A1 domain) – Research Grade Biosimilar

CATALOG NUMBER: 10-476

Clonality:
Recombinant Monoclonal
Conjugate:
Unconjugated
Specifications
source-species:
CHO cells
source-species:
CHO cells
Immunogen:
Humanized / VWF A1 domain [Homo sapiens]
Conjugate:
Unconjugated
Purification:
>95%
Clonality:
Recombinant Monoclonal
Isotype:
VH-VH
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Storage Conditions:
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for 1-2 weeks. Store at -20 °C for 12 months. Store at -80 °C for long term storage.
Additional Names:
ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp
User Note:
Optimal dilutions for each application to be determined by the researcher.
Background:
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

FOR RESEARCH USE ONLY

For additional information, visit ProSci’s Terms & Conditions Page.

Disclaimer:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

CATALOG NUMBER:

10-476

List Size:
0.1 mg

List Price:

$515.00

Shipping Info
Customize your order
Custom Antibody Services

New & Featured Products

CATALOG NUMBER: PM-7369-HRP

CATALOG NUMBER: PM-7369-biotin

CATALOG NUMBER: PM-7369